Satoshi Yoda
9PUBLICATIONS
58CO-AUTHORS
Get your video featured.
Publish with JoVEGet your video featured.
Publish with JoVE
Publications (9)
Sort by Publication Date:
|Sep 13, 2024
NVL-655 Is a Selective and Brain-Penetrant Inhibitor of Diverse ALK-Mutant Oncoproteins, Including Lorlatinib-Resistant Compound Mutations.Jessica J Lin, Joshua C Horan, Anupong Tangpeerachaikul
|Dec 13, 2022
NVL-520 Is a Selective, TRK-Sparing, and Brain-Penetrant Inhibitor of ROS1 Fusions and Secondary Resistance Mutations.Alexander Drilon, Joshua C Horan, Anupong Tangpeerachaikul
|Jun 21, 2022
Analysis of lorlatinib analogs reveals a roadmap for targeting diverse compound resistance mutations in ALK-positive lung cancer.Aya Shiba-Ishii, Ted W Johnson, Ibiayi Dagogo-Jack
|Mar 09, 2021
Spectrum of Mechanisms of Resistance to Crizotinib and Lorlatinib in ROS1 Fusion-Positive Lung Cancer.Jessica J Lin, Noura J Choudhury, Satoshi Yoda
|Aug 18, 2020
Small cell transformation of ROS1 fusion-positive lung cancer resistant to ROS1 inhibition.Jessica J Lin, Adam Langenbucher, Pranav Gupta
|Feb 23, 2020
MET Alterations Are a Recurring and Actionable Resistance Mechanism in ALK-Positive Lung Cancer.Ibiayi Dagogo-Jack, Satoshi Yoda, Jochen K Lennerz
Pageof 2
Frequent Collaborators
6 joint publications
Jessica J Lin
3 joint publications
Alexander Drilon
3 joint publications
Aaron N Hata
3 joint publications
Jochen K Lennerz
3 joint publications
Andrew Do
2 joint publications
Luc Friboulet
2 joint publications
Lecia V Sequist
2 joint publications
Sai-Hong Ignatius Ou
2 joint publications
Kylie Prutisto-Chang
2 joint publications
Subba R Digumarthy
